Financial Analysis

COMMITMENTS AND CONTINGENCIES Contingencies On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York (the EDNY Court) against the Company and certain individual defendants. The case was narrowed following its inception. The plaintiffs claims which, as discussed below, have now been approved for final settlement, were that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (Sirona) with DENTSPLY International Inc. (the Merger) and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleged that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserted claims on behalf of a putative class consisting of all purchasers of the Companys stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, wit …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

BENEFIT PLANS Defined Contribution Plans The Company maintains both U.S. and non-U.S. employee defined contribution plans. The primary U.S. plan, the Dentsply Sirona Inc. 401(k) Savings Plan (the Plan), allows eligible employees to contribute a portion of their cash compensation to the Plan on a tax-deferred basis, and the Company provides a matching contribution. The Plan includes various investment funds. Each eligible participant who elects to contribute to the Plan will receive a matching contribution of 100% on the first 4% contributed and 50% on the next 2% contributed for a total maximum matching contribution of 5%. At its discretion, the Company may make additional non-elective cash contributions based on a percentage of compensation to participant accounts. The Company did not make any additional non-elective cash contributions in connection with 2025 compensation. In addition to the Plan, the Company also maintains various other U.S. and non-U.S. defined contribution and non-qualified deferred compensation plans. The annual expenses, net of forfeitures, of these plans were $38 million, $34 million and $43 million for the years ended December 31, 2025, 2024, and 2023, respectively. Defined Benefit Plans The Company maintains defined benefit pension plans for certain employees in Austria, France, Germany, Indonesia, Italy, Japan, the Netherlands, Norway, Sweden, Switzerland, Taiwan, and the United States. These plans provide benefits based upon age, years of service a …

CompensationAndEmployeeBenefitPlansTextBlock · excerpt; the full note is in the filing

FINANCING ARRANGEMENTS Notes Payable and Current Portion of Long-Term Debt Notes payable and current portion of long-term debt was as follows: Year Ended December 31, 2025 2024 Principal Interest Principal Interest (in millions except percentages) Balance Rate Balance Rate Corporate commercial paper facility $ 82 4.4 % $ 410 5.3 % Other short-term borrowings 3 4.5 % 11 4.9 % Add: Current portion of long-term debt 228 128 Total notes payable and current portion of long-term debt $ 313 $ 549 Average amount of short-term debt outstanding during the year 136 344 Weighted-average interest rate on short-term debt at year-end 4.4 % 5.3 % Short-Term Financing The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $700 million, that expires on May 12, 2028. The Company also has a $700 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $700 million total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had outstanding borrowings of $82 million and $410 million under the commercial paper facility at December 31, 2025 and December 31, 2024, respectively, and no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $22 million in uncommitted short-term financing available under lines of cre …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Net sales disaggregated by product category were as follows: Year Ended December 31, (in millions) 2025 2024 2023 Equipment & Instruments $ 578 $ 553 $ 628 CAD/CAM 458 509 541 Connected Technology Solutions $ 1,036 $ 1,062 $ 1,169 Essential Dental Solutions $ 1,469 $ 1,454 $ 1,468 Orthodontics $ 227 $ 299 $ 339 Implants & Prosthetics 623 674 701 Orthodontic and Implant Solutions $ 850 $ 973 $ 1,040 Wellspect Healthcare $ 325 $ 304 $ 288 Total net sales $ 3,680 $ 3,793 $ 3,965

DisaggregationOfRevenueTableTextBlock

STOCK COMPENSATION The Company maintains the 2024 Omnibus Incentive Plan (the Plan), which was approved by the Companys stockholders on May 22, 2024 (the Effective Date). The Companys stockholders previously approved the 2016 Omnibus Incentive Plan (the Prior Plan). After the Effective Date, no new awards may be granted under the Prior Plan, although awards granted under the Prior Plan prior to the Effective Date remain outstanding and remain subject to the terms and conditions of, and continue to be governed by, the Prior Plan. Under the Plan, the Company may grant stock options, share appreciation rights, restricted shares, restricted share units, share bonuses, other share-based awards, or cash awards, collectively referred to as Awards. The Companys non-qualified stock options (NQSOs) are granted at exercise prices that are at least equal to the closing stock price on the date of grant. Under the Plan, 14.5 million shares are initially available for Awards, less (i) one share for every one share that was subject to an option or share appreciation right granted after March 26, 2024 under the Prior Plan and (ii) 2.7 shares for every one share that was subject to an award other than an option or share appreciation right granted after March 26, 2024 under the Prior Plan (such adjusted amount, the Share Pool). Under the Plan, any shares that are subject to options or share appreciation rights shall be counted against the Share Pool as one share for every one share granted, and …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

FAIR VALUE MEASUREMENT The estimated fair and carrying values of the Companys total debt were $2,217 million and $2,329 million, respectively, at December 31, 2025. At December 31, 2024, the estimated fair and carrying values were $2,037 million and $2,135 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at December 31, 2025 to companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes. Assets and liabilities measured at fair value on a recurring basis The Companys financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: Year Ended December 31, 2025 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swap asset related to long-term debt $ 14 $ $ 14 $ Foreign exchange forward contracts 8 8 Total assets $ 22 $ $ 22 $ Liabilities Interest rate swaps $ 14 $ $ 14 $ Cross currency basis swaps 31 31 Foreign exchange forward contracts 67 67 Contingent considerations on acquisitions Total liabilities $ 112 $ $ 112 $ Year Ended December 31, 2024 (in millions) Total Level 1 Level 2 Level 3 Assets Cross currency interest rate swaps $ 18 $ $ 18 $ Foreign exchange forward contracts 18 18 Total assets $ 36 $ $ 36 $ Liabilities Interest rate swaps $ 21 $ $ 21 $ Foreign exchange forward contract …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

GOODWILL AND INTANGIBLE ASSETS The Companys policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate an asset might be impaired. Impairment charges are recorded in Goodwill and intangible asset impairment in the Consolidated Statement of Operations. Impairment during the Three Months Ended June 30, 2025 For the three months ended June 30, 2025, the Company assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2025. As a result of the Companys April 1 impairment test, it was determined that the fair values of its Implant & Prosthetic Solutions reporting unit and certain indefinite-lived intangible assets, including trade names and trademarks within the Connected Technology Solutions segment, and certain trade names within the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment were below their carrying values. The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was primarily driven by the impact of tariffs and lower projected volumes, due partly to competitive pressures, particularly in the United States and European markets. These factors contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows in the near term. As a …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

INCOME TAXES The components of loss before income taxes were as follows: Year Ended December 31, (in millions) 2025 2024 2023 United States $ (120) $ (307) $ (6) Foreign (366) (629) (169) Total loss before income taxes $ (486) $ (936) $ (175) The components of the expense (benefit) for income taxes from operations were as follows: Year Ended December 31, (in millions) 2025 2024 2023 Current: U.S. federal $ (1) $ (6) $ 1 U.S. state 2 1 Foreign 81 115 86 Total $ 82 $ 110 $ 87 Deferred: U.S. federal $ 36 $ (61) $ 4 U.S. state 2 (1) (3) Foreign (8) (74) (131) Total $ 30 $ (136) $ (130) Total expense (benefit) for income taxes $ 112 $ (26) $ (43) For the year ended December 31, 2025, the reconciliation of the U.S. federal statutory tax rate to the effective rate was as follows: Year Ended December 31, (in millions, except percentages) 2025 Statutory U.S. federal income tax rate $ (102) 21.0 % Effect of: State income taxes, net of federal benefit (a) 3 (0.6) % Foreign tax effects Germany Statutory income tax rate differential 16 (3.3) % Trade tax (18) 3.7 % Changes in valuation allowances 16 (3.3) % Goodwill impairment 8 (1.6) % Other 2 (0.4) % Israel Statutory income tax rate differential 16 (3.3) % Goodwill impairment 18 (3.7) % Other (4) 0.8 % Luxembourg Changes in valuation allowance 238 (48.9) % Local impairment losses (250) 51.3 % Foreign exchange differences 11 (2.3) % Other 3 (0.6) % Sweden Goodwill impairment 26 (5.3) % Other 2 (0.4) % Switzerland Statutory income tax rate …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

LEASES The net present value of finance and operating lease right-of-use assets and liabilities was as follows: Year Ended December 31, (in millions, except percentages) Location in the Consolidated Balance Sheets 2025 2024 Assets Finance leases Property, plant, and equipment, net $ $ Operating leases Operating lease right-of-use assets, net 139 136 Total right-of-use assets $ 139 $ 136 Liabilities Current liabilities Operating leases Accrued liabilities 47 46 Noncurrent liabilities Finance leases Long-term debt Operating leases Operating lease liabilities 93 91 Total lease liabilities $ 140 $ 137 Supplemental information: Weighted-average discount rate Operating leases 4.6 % 4.1 % Weighted-average remaining lease term in years Operating leases 4.0 4.1 The lease costs recognized in the Consolidated Statements of Operations were as follows: Year Ended December 31, (in millions) 2025 2024 Operating lease cost $ 65 $ 67 Variable lease cost 17 16 Total lease cost $ 82 $ 83 The contractual maturity dates of the remaining lease liabilities as of December 31, 2025 were as follows: (in millions) Operating Leases 2026 $ 52 2027 38 2028 26 2029 17 2030 9 2031 and beyond 12 Total lease payments $ 154 Less imputed interest 14 Present value of lease liabilities $ 140 The supplemental cash flow information for leases was as follows: Year Ended December 31, (in millions) 2025 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for oper …

LesseeOperatingLeasesTextBlock · excerpt; the full note is in the filing

Recently Adopted Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose additional income tax information, primarily related to the income tax rate reconciliation and income taxes paid on an annual basis. The amendments are intended to enhance the transparency and decision-usefulness of income tax disclosures. The Company has adopted this accounting standard as of January 1, 2025, which impacts annual disclosures only and does not impact results of operations, financial position, or cash flow, and the related disclosures are included in Note 16, Income Taxes in the Notes to the Consolidated Financial Statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of information about significant expenses in a public companys reportable segment results on both an interim and annual basis. Public companies are required to disclose significant expense categories and amounts for each reportable segment. Significant expense categories are derived from expenses that are regularly reported to an entitys chief operating decision-maker (CODM) and included in a segments reported measures of profit or loss. Public entities are also required to disclose the title and position of the CODM and explain how the CODM uses t …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

REVENUE RECOGNITION Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. Net sales disaggregated by product category were as follows: Year Ended December 31, (in millions) 2025 2024 2023 Equipment & Instruments $ 578 $ 553 $ 628 CAD/CAM 458 509 541 Connected Technology Solutions $ 1,036 $ 1,062 $ 1,169 Essential Dental Solutions $ 1,469 $ 1,454 $ 1,468 Orthodontics $ 227 $ 299 $ 339 Implants & Prosthetics 623 674 701 Orthodontic and Implant Solutions $ 850 $ 973 $ 1,040 Wellspect Healthcare $ 325 $ 304 $ 288 Total net sales $ 3,680 $ 3,793 $ 3,965 Net sales disaggregated by geographic region were as follows: Year Ended December 31, (in millions) 2025 2024 2023 United States $ 1,182 $ 1,348 $ 1,437 Europe 1,576 1,518 1,550 Rest of World 922 927 978 Total net sales $ 3,680 $ 3,793 $ 3,965 Contract Assets and Liabilities The Company does not typically have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to deferred revenue associated with loyalty points earned but not yet redeemed by customers under the Companys loyalty point program and advanced billings for customer orthodontic treatments where the performance obligation has not yet been satisfied. The Company had deferred …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

SEGMENT AND GEOGRAPHIC INFORMATION The Company has four operating segments, organized primarily by product, which are also the Companys reportable segments. These are (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare. They generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight with the exception of Wellspect Healthcare, which has a more discrete market and regulatory environment specific to the medical device industry. These operating segments, which also form the Companys reportable segments, are identified in accordance with how the Companys chief operating decision maker (CODM) regularly reviews financial results and uses this information to evaluate the Companys performance and allocate resources. The Companys CODM is the Chief Executive Officer. The CODM assesses performance of the segments based on the net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain unallocated corporate costs, interest expense, net, other (income) expense, net, goodwill and intangible asset impairments, restructuring and other costs, amortization of intangible assets, other acquisition costs, and depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations. Asset and other balance sheet information is not repor …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

SIGNIFICANT ACCOUNTING POLICIES Description of Business DENTSPLY SIRONA Inc. (Dentsply Sirona or the Company), is the worlds largest diversified manufacturer of dental products and technologies, with a 139-year history of innovation and service to the dental industry and patients worldwide. The Companys principal product categories include dental consumable products, dental equipment, dental technologies and continence care consumable products. The Company sells its products in approximately 140 countries under some of the most well-established brand names in the industry. Basis of Presentation The consolidated financial statements include the results of the Company and its consolidated subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. Certain prior period amounts have been reclassified to conform to current year presentation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (US GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents include deposits with banks as well as highly li …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

EQUITY On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. At December 31, 2025, the Company had authorization to repurchase $1.2 billion in shares of common stock remaining under the share repurchase program. On March 3, 2023, the Company entered into an Accelerated Share Repurchase Agreement (ASR Agreement) with a financial institution to repurchase the Companys common stock. The Company repurchased shares under the ASR Agreement as part of the share repurchase program described above. In 2023, the Company repurchased approximately 3.1 million shares, which were delivered during March 2023, at a volume-weighted average price of $38.74, representing $120 million of the total anticipated repurchase size. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement, resulting in a total of 3.9 million shares repurchased under the agreement. (in millions, except per share amounts) Initial Delivery Final Settlement Agreement Date Amount Paid Shares Received Price per share Value of Shares as a % of Contract Value Settlement Date Total Shares Received Aver …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

SUBSEQUENT EVENTS On February 23, 2026, the Companys Board of Directors eliminated the declaration of quarterly dividends on the Companys common stock starting in the quarter ending March 31, 2026. On February 24, 2026, the Companys Board of Directors approved a restructuring plan (the 2026 Plan) to improve operational performance and drive stockholder value creation. In connection with the 2026 Plan, the Company expects to incur non-recurring charges in the approximate range of $55 million to $65 million, the majority of which will be expensed and paid in cash in 2026 and 2027. …

SubsequentEventsTextBlock · excerpt; the full note is in the filing

COMMITMENTS AND CONTINGENCIES Contingencies On December 19, 2018, a putative class action was filed in the U.S. District Court for the Eastern District of New York (the EDNY Court) against the Company and certain individual defendants. The case was narrowed following its inception. The plaintiffs claims which, as discussed below, have now been approved for final settlement, were that the Company and certain individual defendants violated U.S. securities laws by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (Sirona) with DENTSPLY International Inc. (the Merger) and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products. In addition, the plaintiff alleged that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between May 6, 2016 and August 7, 2018. The plaintiff asserted claims on behalf of a putative class consisting of all purchasers of the Companys stock during the period from December 8, 2015 through August 6, 2018. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, wit …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

FINANCING ARRANGEMENTS The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of $700 million, that expires on May 12, 2028. The Company also has a $700 million commercial paper program. The $700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of $700 million as the total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had no outstanding borrowings under the commercial paper facility at September 30, 2025 and $410 million in outstanding borrowings under the commercial paper facility at December 31, 2024, and the Company had no outstanding borrowings under the multi-currency revolving credit facility at September 30, 2025 and December 31, 2024. The Company also has access to $42 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by other outstanding short-term borrowings of $5 million. On March 19, 2025, the Company entered into a 364-day term loan of $435 million with a maturity date of March 18, 2026 (the Bridge Loan Facility). The proceeds were $432 million, net of issuance fees totaling $3 million. The net proceeds from the Bridge Loan Facility were used to repay indebtedness under the Companys commercial paper facility and pre-fund repayment of certain other short-term indebtedness. Subseque …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Net sales disaggregated by product category were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 Equipment & Instruments $ 148 $ 138 $ 418 $ 402 CAD/CAM 111 131 319 367 Connected Technology Solutions 259 269 $ 737 $ 769 Essential Dental Solutions 357 369 $ 1,097 $ 1,108 Orthodontics 53 83 $ 175 $ 276 Implants & Prosthetics 152 158 473 512 Orthodontic and Implant Solutions 205 241 $ 648 $ 788 Wellspect Healthcare 83 72 $ 237 $ 223 Total net sales $ 904 $ 951 $ 2,719 $ 2,888

DisaggregationOfRevenueTableTextBlock

STOCK-BASED COMPENSATION The amounts of stock-based compensation expense recorded in the Companys Consolidated Statements of Operations were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 Cost of products sold $ 1 $ $ 2 $ 2 Selling, general, and administrative expense 5 11 22 31 Research and development expense 1 1 2 Total stock-based compensation expense $ 6 $ 12 $ 25 $ 35 …

DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock · excerpt; the full note is in the filing

FAIR VALUE MEASUREMENT The estimated fair and carrying values of the Companys total debt were $2,334 million and $2,395 million, respectively, at September 30, 2025. At December 31, 2024, the estimated fair and carrying values were $2,037 million and $2,135 million, respectively. The fair value of long-term debt is determined by discounting future cash flows using interest rates available at September 30, 2025 and December 31, 2024 and interest rates for companies with similar credit ratings for issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes. Assets and liabilities measured at fair value on a recurring basis The Companys financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: September 30, 2025 (in millions) Total Level 1 Level 2 Level 3 Assets Cross currency basis swaps $ 41 $ $ 41 $ Foreign exchange forward contracts $ 4 $ $ 4 $ Total assets $ 45 $ $ 45 $ Liabilities Interest rate swaps $ 14 $ $ 14 $ Cross currency basis swaps 88 88 Foreign exchange forward contracts 77 77 Total liabilities $ 179 $ $ 179 $ December 31, 2024 (in millions) Total Level 1 Level 2 Level 3 Assets Cross currency basis swaps $ 18 $ $ 18 $ Foreign exchange forward contracts 18 18 Total assets $ 36 $ $ 36 $ Liabilities Interest rate swaps $ 21 $ $ 21 $ Foreign exchange forward contracts 9 9 Contingent consideration on acquisiti …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

GOODWILL AND INTANGIBLE ASSETS The Companys policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, with more frequent assessments if events or changes in circumstances indicate a given asset might be impaired. For the goodwill impairment tests as of April 1, 2025, the Company utilized an income-based approach for the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment and performed a qualitative assessment for the other two reporting units with goodwill balances, due to the significant excess of fair value over carrying value for those units. As a result of the annual goodwill impairment test, the Company determined that the fair value of the Implant & Prosthetic Solutions reporting unit was below its carrying value. Fair value was determined using a discounted cash flow model based on inputs developed from internal and market-based data, including ten-year forecasted cash flows plus a terminal value based on capitalizing the last periods cash flows using a perpetual growth rate. The Companys significant assumptions in the discounted cash flow model included, but were not limited to, a discount rate of 12.5%, revenue growth rates (including perpetual growth rates), operating margin percentages, and net working capital changes of the reporting units business. The reduction in fair value for the Implant & Prosthetic Solutions reporting unit determined by this model was …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

INCOME TAXES The effective tax rates for the three months ended September 30, 2025 and 2024 were (86.5%) and (3.3%), respectively. For the nine months ended September 30, 2025 and 2024 the rates were (33.6%) and (16.7%), respectively. The decrease in effective tax rate is primarily driven by intangible and goodwill impairment.

IncomeTaxDisclosureTextBlock

Recently Adopted Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose additional income tax information, primarily related to the income tax rate reconciliation and income taxes paid on an annual basis. The amendments are intended to enhance the transparency and decision-usefulness of income tax disclosures. The Company has adopted this accounting standard as of January 1, 2025, which impacts annual disclosures only. This update did not have an impact to results of operations, financial position, or cash flows. Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU No. 2024-03, Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses for public business entities (PBEs). In January 2025, the FASB issued ASU No. 2025-01 Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40), which clarified the effective date for ASU No. 2024-03. These amendments are intended to provide more information about types of expenses in commonly presented expense captions. The amendments in this update are effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beg …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

REVENUE RECOGNITION Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. Net sales disaggregated by product category were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 Equipment & Instruments $ 148 $ 138 $ 418 $ 402 CAD/CAM 111 131 319 367 Connected Technology Solutions 259 269 $ 737 $ 769 Essential Dental Solutions 357 369 $ 1,097 $ 1,108 Orthodontics 53 83 $ 175 $ 276 Implants & Prosthetics 152 158 473 512 Orthodontic and Implant Solutions 205 241 $ 648 $ 788 Wellspect Healthcare 83 72 $ 237 $ 223 Total net sales $ 904 $ 951 $ 2,719 $ 2,888 Net sales disaggregated by geographic region were as follows: Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 United States $ 291 $ 374 $ 886 $ 1,089 Europe 382 347 1,148 1,110 Rest of World 231 230 685 689 Total net sales $ 904 $ 951 $ 2,719 $ 2,888 Contract Assets and Liabilities The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to deferred revenue associated with loyalty points earned but not yet redeemed by customers under the Companys loyalty point program and advanced billi …

RevenueFromContractWithCustomerTextBlock · excerpt; the full note is in the filing

SEGMENT INFORMATION The Company has four operating segments, organized primarily by product, which are also the Companys reportable segments. These are (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare. These operating segments are identified in accordance with how the Companys chief operating decision maker (CODM) regularly reviews financial results and uses this information to evaluate the Companys performance and allocate resources. The Companys CODM is the Chief Executive Officer. The Companys reportable segment information was as follows: Three Months Ended September 30, (in millions) 2025 Connected Technology Solutions Essential Dental Solutions Orthodontic and Implant Solutions Wellspect Healthcare Total Net sales $ 259 $ 357 $ 205 $ 83 $ 904 Adjusted cost of products sold (a) 157 140 95 33 Adjusted selling expenses (b) 55 77 56 13 Adjusted G&A expenses (b) 20 18 20 7 Adjusted R&D expenses (c) 17 6 12 2 Segment adjusted operating income $ 10 $ 116 $ 22 $ 28 $ 176 Reconciling items (income) expense: Unallocated corporate costs (d) $ 69 Interest expense, net 23 Other income (11) Goodwill and intangible asset impairments 262 Restructuring and other costs 5 Amortization of intangibles 57 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations 1 Loss before income taxes $ (230) (a) Adjusted cost of products sold represents …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

BUSINESS AND BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and the rules of the U.S. Securities and Exchange Commission (SEC). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Certain prior period amounts have been reclassified to conform to current year presentation. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (Dentsply Sirona or the Company) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Companys most recent Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 27, 2025 (the 2024 Form 10-K). Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net sales and expense during the reporting period. Act …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing